Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

Author： Lynd Larry D.   Najafzadeh Mehdi   Colley Lindsey   Byrne Michael F.   Willan Andrew R.   Sculpher Mark J.   Johnson F. Reed   Hauber A. Brett  

Publisher： Blackwell Publishing

ISSN： 1098-3015

Source： Value in Health, Vol.13, Iss.4, 2010-06, pp. : 411-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome

By Lea R.   Whorwell P.J.  

Drug Safety, Vol. 27, Iss. 4, 2004-01 ,pp. : 229-242

Adis International

Access to resources Recommend Favorite

Alosetron and irritable bowel syndrome

By Mayer Emeran A   Bradesi Sylvie  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. : 2089-2098

Informa Healthcare

Access to resources Recommend Favorite

Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies

By Kodell Ralph L.   Chen James J.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 1, 2013-01 ,pp. : 231-238

Taylor & Francis Ltd

Access to resources Recommend Favorite

Benefit-Risk Analysis: A Brief Review and Proposed Quantitative Approaches

By Holden W.L.  

Drug Safety, Vol. 26, Iss. 12, 2003-01 ,pp. : 853-862

Adis International

Access to resources Recommend Favorite

Alosetron in Irritable Bowel Syndrome: Strategies for its Use in a Common Gastrointestinal Disorder

By Lembo A.  

Drugs, Vol. 63, Iss. 18, 2003-01 ,pp. : 1895-1905

Adis International

Access to resources Recommend Favorite